Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Acecainide Hydrochloride
2. Acecainide Monohydrochloride
3. Acetylprocainamide
4. Hydrochloride, Acecainide
5. Monohydrochloride, Acecainide
6. N Acetylprocainamide
7. N-acetylprocainamide
1. N-acetylprocainamide
2. 32795-44-1
3. Napa
4. Acekainid
5. Acecainida
6. Acecainidum
7. N-acetyloprokainamid
8. Acetylprocainamide
9. Acecainide [inn]
10. 4'-((2-(diethylamino)ethyl)carbamoyl)acetanilide
11. N-acetylprocaine Amide
12. 4-acetamido-n-[2-(diethylamino)ethyl]benzamide
13. Acecainide;napa
14. Benzamide, 4-(acetylamino)-n-(2-(diethylamino)ethyl)-
15. N-acetylnovocainamide
16. N-acetyl-procainamide
17. Chebi:60728
18. Acetylprocainamide, N-
19. N-[2-(diethylamino)ethyl]-4-acetamidobenzamide
20. Chembl1097
21. Mls000069490
22. 910q707v6f
23. Acetanilide, 4'-((2-(diethylamino)ethyl)carbamoyl)-
24. Smr000059070
25. Acekainid [polish]
26. Acecainidum [inn-latin]
27. Acecainida [inn-spanish]
28. N-acetyloprokainamid [polish]
29. 4-acetamido-n-(2-(diethylamino)ethyl)benzamide
30. Brn 2868559
31. Unii-910q707v6f
32. Procainamide-n-acetyl
33. N-acetyl Procainamide
34. Acecainide [mi]
35. Opera_id_1541
36. Spectrum3_001843
37. Lopac-a-5909
38. Epitope Id:140121
39. Acecainide [who-dd]
40. Lopac0_000009
41. Bspbio_003226
42. Mls001146871
43. Schembl156943
44. N-acetylprocainamide, >=99%
45. Dtxsid6048414
46. Kbio3_002726
47. Hms2232g18
48. Hms3372e09
49. Bcp26213
50. Hy-b1109
51. Zinc1999404
52. Bdbm50151860
53. Akos016614968
54. N-acetyl Procainamide(<30%)
55. Ccg-204105
56. Cs-4707
57. Sdccgsbi-0049998.p003
58. Ncgc00015072-01
59. Ncgc00015072-02
60. Ncgc00015072-03
61. Ncgc00015072-04
62. Ncgc00015072-05
63. Ncgc00015072-06
64. Ncgc00015072-07
65. Ncgc00015072-13
66. Ncgc00023226-03
67. Ncgc00023226-04
68. As-57414
69. Sbi-0049998.p002
70. Db-048268
71. N-acetylprocainamide 1.0 Mg/ml In Methanol
72. Ft-0639052
73. Ab00384286_20
74. 4-acetylamino-n-(2-diethylamino-ethyl)-benzamide
75. A905428
76. J-018880
77. Q4726688
78. 4-(acetylamino)-n-[2-(diethylamino)ethyl]benzamide #
79. Brd-k07753030-003-01-0
80. Brd-k07753030-003-11-9
81. Z26393212
82. N-(4-{[2-(diethylamino)ethyl]carbamoyl}phenyl)ethanimidic Acid
Molecular Weight | 277.36 g/mol |
---|---|
Molecular Formula | C15H23N3O2 |
XLogP3 | 0.7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 7 |
Exact Mass | 277.17902698 g/mol |
Monoisotopic Mass | 277.17902698 g/mol |
Topological Polar Surface Area | 61.4 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 308 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Acecainide is a known human metabolite of Procainamide.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?